X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Pacific Biosciences Enables Reference-Quality De Novo Human Genome Assemblies

Monday, March 2, 2015

MENLO PARK, Calif., March 2, 2015 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of the PacBio® RS II Sequencing System, today announced that its Single Molecule, Real-Time (SMRT®) Sequencing was featured in a number of presentations during last week’s Advances in Genome Biology & Technology (AGBT) conference, including demonstrations of the technology’s ability to create reference-quality de novo human genome assemblies.

Presentations at the conference highlighted the power of PacBio’s long and accurate sequencing reads to resolve difficult regions and access novel genetic variation. At the company’s workshop, J. Craig Venter, Ph.D., of Human Longevity, Inc. presented data about his highly studied genome, which has now been sequenced using the PacBio RS II and assembled in the cloud on the DNAnexus platform, creating a higher resolution version of this reference genome at a fraction of the original time and cost. Deanna Church, Ph.D., who has played a key role in the public efforts to create a human reference genome, discussed the importance of having more high-quality de novo human genomes, and Gene Myers, Ph.D., from the Max Planck Institute discussed his work to develop computational methods to enable perfect assemblies using SMRT
Sequencing data. To highlight the importance of population-specific reference genomes, Jeong-Sun Seo, M.D., Ph.D., of the Seoul National University College of Medicine and co-founder of Macrogen, Inc. discussed progress with the Asian Genome Project, which is also using the PacBio RS II for de novo genome assembly of Asian subpopulations. In addition, W. Richard McCombie from Cold Spring Harbor presented analysis of structural re-arrangements and gene amplifications in a breast cancer cell line genome.

“As a result of continual performance improvements with the PacBio RS II, it is now feasible to return to reference-quality de novo human genome assemblies and no longer rely on a single reference genome that does not adequately represent the variation in the global population,” said Michael Hunkapiller, Ph.D., CEO of Pacific Biosciences. “With the performance improvements planned for this year, we expect the cost to generate a human genome on the PacBio RS II to drop to around $10,000, which is not a high premium to pay for the superior quality and completeness that SMRT Sequencing provides. This cost will only continue to drop as we maintain our track record of performance improvements.”

Evan Eichler, Ph.D., from the University of Washington presented more data about his work on characterizing complex variation in the human genome using SMRT Sequencing. This work was originally published in the journal Nature. In the poster sessions, Mark Salit, Ph.D., from the National Institute for Standards and Technology and Robert Sebra, Ph.D., from the Icahn School of Medicine at Mount Sinai discussed aspects of their collaboration to create a genome reference for the Ashkenazi Jewish population using a mother, father,
child trio. In addition, the Genome Reference Consortium presented de novo assemblies for two human cell lines targeted for “platinum-grade” references.

Jonas Korlach, Ph.D., Chief Scientific Officer of Pacific Biosciences, added: “We are excited to see how our customers are using SMRT Sequencing for an increasing number of important human and other complex genome studies, including characterizing variation beyond SNPs, developing population-specific genome references, and resolving the genetic basis of disease. We are also delighted to support the efforts by many in the community to raise the bar on the completeness and quality of genome information.”

More information about the data presented at the workshop is available here: https://go.pardot.com/l/1652/2015-02-23/312lbw. To learn more about how to access PacBio de novo genome assembly data using the DNAnexus cloud-based platform, please visit: https://dnanexus.com/falcon.

About Pacific Biosciences  

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio® RS II Sequencing System to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, the company’s products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes in the most comprehensively studied human cell lines; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Our technology provides the
industry’s highest consensus accuracy and longest read lengths along with the ability to detect real-time kinetic information. The PacBio RS II System, including consumables and software provides a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses for, performance of, and cost of using the Company’s products and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and could materially affect actual results. Factors that could materially affect actual results can be found in our most recent filings with the Securities and Exchange Commission, including our most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” The Company undertakes no obligation to update forward-looking statements.

CONTACT: For Pacific Biosciences:

         Media:

         Nicole Litchfield

         415.793.6468

         nicole@bioscribe.com



         Investors:

         Trevin Rard

         650.521.8450

         ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media

Press Release

Pacific Biosciences Announces New Chief Financial Officer

Monday, September 14, 2020

Stay
Current

Visit our blog »